RDY Announces Launch of India’s First DCGI‑Approved Semaglutide Injection Obeda® for Type 2 Diabetes, Phase‑III Study Shows Non‑Inferior Efficacy, 2 mg/4 mg Pen Delivers 4 Doses, INR 4,200/Month Cost, Building GLP‑1 Portfolio Across Metabolic Disorders
Dr. Reddy's Laboratories Limited American Depositary Shares · Now $13.63
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS